Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 5/20 | 0.42 |
| ▸ | JAK3 | P52333 | 5/20 | 0.42 |
| ▸ | PTK2 | Q05397 | 5/20 | 0.42 |
| ▸ | CCR2 | P41597 | 14/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26072412 | 1.00 | JAK2 (0.42) | JAK2JAK3PTK2CCR2PTGS2 | |
| SCHEMBL26072099 | 0.90 | JAK2 (0.39) | JAK2JAK3PTK2PTGS2 | |
| SCHEMBL29394099 | 0.90 | JAK2 (0.39) | JAK2JAK3PTK2PTGS2 | |
| SCHEMBL26072623 | 0.88 | CCR2 (0.47) | JAK2JAK3PTK2CCR2 | |
| SCHEMBL29393849 | 0.88 | CCR2 (0.47) | JAK2JAK3PTK2CCR2 | |
| SCHEMBL29395751 | 0.87 | CCR2 (0.42) | JAK2JAK3PTK2CCR2 | |
| SCHEMBL29394205 | 0.87 | TLR9 (0.41) | JAK2JAK3PTK2 | |
| SCHEMBL26071958 | 0.87 | CCR2 (0.42) | JAK2JAK3PTK2CCR2 | |
| SCHEMBL26072085 | 0.87 | TLR9 (0.41) | JAK2JAK3PTK2 | |
| SCHEMBL26072181 | 0.87 | JAK2 (0.41) | JAK2JAK3PTK2CCR2PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4200298-B1 | 1H-PYRROLO[3,2-C]PYRIDINE AND 1H-PYRROLO[2,3-C]PYRIDINE DERIVATIVES AS TLR9 INHIBITORS FOR THE TREATMENT OF FIBROSIS | BRISTOL MYERS SQUIBB CO (US) | 2025-05-21 | — | — | EP | claimed |
| EP-4200298-A1 | 1H-PYRROLO[3,2-C]PYRIDINE AND 1H-PYRROLO[2,3-C]PYRIDINE DERIVATIVES AS TLR9 INHIBITORS FOR THE TREATMENT OF FIBROSIS | Bristol-Myers Squibb Company (US) | 2023-06-28 | — | — | EP | claimed |
| CN-115867549-A | 1H-pyrrolo [3,2-c ] pyridine and 1H-pyrrolo [2,3-c ] pyridine derivatives as TLR9 inhibitors for the treatment of fibrosis | 百时美施贵宝公司 | 2023-03-28 | — | — | CN | claimed |
| WO-2022040267-A1 | 1H-PYRROLO[3,2-C]PYRIDINE AND 1H-PYRROLO[2,3-C]PYRIDINE DERIVATIVES AS TLR9 INHIBITORS FOR THE TREATMENT OF FIBROSIS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-02-24 | — | — | WO | claimed |
| EP-4200298-A1 | 1H-PYRROLO[3,2-C]PYRIDINE AND 1H-PYRROLO[2,3-C]PYRIDINE DERIVATIVES AS TLR9 INHIBITORS FOR THE TREATMENT OF FIBROSIS | Bristol-Myers Squibb Company (US) | 2023-06-28 | — | — | EP | disclosed |
| CN-115867549-A | 1H-pyrrolo [3,2-c ] pyridine and 1H-pyrrolo [2,3-c ] pyridine derivatives as TLR9 inhibitors for the treatment of fibrosis | 百时美施贵宝公司 | 2023-03-28 | — | — | CN | disclosed |
| WO-2022040267-A1 | 1H-PYRROLO[3,2-C]PYRIDINE AND 1H-PYRROLO[2,3-C]PYRIDINE DERIVATIVES AS TLR9 INHIBITORS FOR THE TREATMENT OF FIBROSIS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-02-24 | — | — | WO | disclosed |